Andrew Guggenhime - Aug 25, 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Role
President and CFO
Signature
Andrew Guggenhime, by /s/ Ron Metzger, Attorney-in-Fact
Stock symbol
PCVX
Transactions as of
Aug 25, 2022
Transactions value $
-$815,400
Form type
4
Date filed
8/29/2022, 05:46 PM
Previous filing
Aug 22, 2022
Next filing
Sep 7, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCVX Common Stock Options Exercise $91.2K +17.1K +40.42% $5.35 59.2K Aug 25, 2022 Direct
transaction PCVX Common Stock Sale -$477K -17.1K -28.79% $28.00 42.2K Aug 25, 2022 Direct F1
transaction PCVX Common Stock Options Exercise $6.93K +1.3K +3.07% $5.35 43.5K Aug 26, 2022 Direct
transaction PCVX Common Stock Sale -$36.3K -1.3K -2.98% $28.00 42.2K Aug 26, 2022 Direct F1
transaction PCVX Common Stock Options Exercise $94.4K +17.7K +41.84% $5.35 59.8K Aug 29, 2022 Direct
transaction PCVX Common Stock Sale -$494K -17.7K -29.5% $28.00 42.2K Aug 29, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Stock Option (right to buy) Options Exercise $0 -17.1K -3.45% $0.00 477K Aug 25, 2022 Common Stock 17.1K $5.35 Direct F2
transaction PCVX Stock Option (right to buy) Options Exercise $0 -1.3K -0.27% $0.00 475K Aug 26, 2022 Common Stock 1.3K $5.35 Direct F2
transaction PCVX Stock Option (right to buy) Options Exercise $0 -17.7K -3.71% $0.00 458K Aug 29, 2022 Common Stock 17.7K $5.35 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter.